- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination with Ipilimumab and Pembrolizumab in Participants with Unresectable or Metastatic Melanoma
This study is testing new combinations of medicines for advanced melanoma, a type of skin cancer that has spread or can't be removed by surgery. It looks at how safe the medicines are and how well they shrink tumours.
For: Unresectable or Metastatic MelanomaGermany · Spain - Active not recruitingPHASE1, PHASE2
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
This study is testing a new drug, BI-1607, combined with two existing cancer drugs, pembrolizumab and ipilimumab, for advanced melanoma. Researchers want to see if this new combination is safe, effective, and helps patients whose cancer hasn't responded to other treatments.
For: Melanoma Metastatic · Melanoma of Skin · Melanoma BRAF V600E/K MutatedGermany · Spain · United Kingdom